JULIANA BRONZATO LUPPI

(Fonte: Lattes)
Índice h a partir de 2011
3
Lattes
Projetos de Pesquisa
Unidades Organizacionais
PAHC, Hospital das Clínicas, Faculdade de Medicina - Médico

Filtros

Limpar filtros

Configurações

Autor: BELDA JR., Walter ×

Resultados de Busca

Agora exibindo 1 - 2 de 2
  • article 4 Citação(ões) na Scopus
    Primary Cutaneous Cryptococcosis Caused by Cryptococcus gatti in an Elderly Patient
    (2022) BELDA JR., Walter; CASOLATO, Ana T. S.; LUPPI, Juliana B.; PASSERO, Luiz Felipe D.; CRIADO, Paulo R.
    According to the spread of Cryptococcus sp., fungal infections can be classified as primary or secondary. In primary cutaneous cryptococcosis, the fungi are restricted to the skin of the patients, without systemic involvement. The incidence of primary cutaneous cryptococcosis is high in patients with immunosuppression, and this type of infection is rarely observed in patients who are immunocompetent. In the present case report, a patient who is immunocompetent and has systemic comorbidity reported that, after skin trauma, ulcerovegetative lesions appeared in the right upper arm; the etiologic agent was identified as Cryptococcus gatti, serotype B. The cutaneous lesions healed completely after 5 months of fluconazole treatment.
  • article 3 Citação(ões) na Scopus
    Managing chromoblastomycosis with acitretin plus imiquimod: A case report on the improvement of cutaneous lesions and reduction of the treatment time
    (2021) BELDA JR., Walter; CASOLATO, Ana Thereza Stradioto; LUPPI, Juliana Bronzato; PASSERO, Luiz Felipe Domingues
    Chromoblastomycosis (CBM) is an infectious disease caused by fungi that is prevalent in tropical and subtropical countries. Besides few therapeutic options, the classical treatment of CBM needs to be administrated for a long period of time, and unfortunately some patients do not show improvement of the lesions. Thus, it becomes urgent to develop new strategies for the treatment of CBM. This work reports a successful treatment, performed with the combination of oral acitretin (50 mg/kg, once a day) plus topical imiquimod (50 mg/g, five times per week) for 5 months in a patient with CBM. A significant improvement of the lesions was observed in the 1st month, and in the 5th a complete regression of lesions was recorded. Changes in the biochemical parameters were not observed. These data suggest that the combination of acitretin and imiquimod may be effective at treating CBM.